Brainstorm Cell reports FY2023 net loss of $17.2M; cash drops to $1.45M; awaits FDA SPA

BRAINSTORM CELL THERAPEUTICS INC.

2024-Q1 EPS reported -$0.05

Net loss $17.2M ($0.40/share) vs $24.3M ($0.66) in 2022; no revenue (pre-revenue biotech).
Cash and equivalents $1.45M at Dec 31, 2023, down from $3M in 2022; raises going-concern risk.
R&D expenses fell to $10.8M from $14M; headcount reduced ~30% in October 2023 strategic realignment.
Submitted SPA request to FDA in Feb 2024 for Phase 3b trial of NurOwn in ALS; awaiting 45-day review.
Withdrew BLA for NurOwn in Oct 2023 after FDA advisory committee voted against effectiveness evidence.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

BRAINSTORM CELL THERAPEUTICS INC. reported the year ended December 31, 2023 results: net income $17.2 million, EPS $0.40.

Period: the year ended December 31, 2023
Net income: $17.2 million
EPS: $0.40
Result: reported results

Exact text from the filing

On April 1, 2024, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-041549

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.